Metrosol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metrosol

Property Description
Active Ingredient Metronidazole
Forms Injection, Tablet, Capsule, Gel
Pharmacological Class Nitroimidazole, Antimicrobial Agent
General Purpose Targeted treatment of infections caused by anaerobic bacteria and protozoa
Origin Synthetic Compound

What Type of Medicine is Metrosol?

Metrosol is a brand name for the medicinal product containing the active ingredient Metronidazole, a prescription-only antimicrobial agent. This compound is entirely synthetic and belongs to the Nitroimidazole pharmacological class, a category clinically recognized for its efficacy against a specific spectrum of pathogens.

The distinctive feature of Metrosol, often positioned as an intravenous (IV) injection, is its role in delivering Metronidazole rapidly into the bloodstream, typically utilized in critical or inpatient care settings. This classification confirms its established therapeutic purpose: the effective control of infections caused by susceptible anaerobic bacteria and protozoal organisms.

Composition and Available Forms of Metronidazole

The core composition of Metrosol centers on the single-ingredient active compound, Metronidazole (C6H9N3O3). While the brand Metrosol frequently refers to the parenteral solution, the active ingredient is widely utilized across diverse dosage forms for oral, topical, and local administration globally.

These preparations include the oral tablet and capsule, intravenous injection, and localized forms like topical cream and vaginal gel. Metronidazole preparations, whether systemic or topical, are essential therapeutic agents.

How Does Metrosol Work (General Principle)?

Metrosol functions as an inactive prodrug. This means it requires chemical reduction and activation by specific enzymes present only within the target anaerobic organisms and protozoa. Once activated, the compound generates cytotoxic free radicals that attack and disrupt the DNA of the harmful microbe, leading to its destruction. This mechanism provides selective toxicity, enabling Metrosol to efficiently eliminate the target pathogens.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Metrosol?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety statements for Metrosol (Metronidazole), based on governmental regulatory sources. All information reflects the drug's established safety profile and is not intended as medical advice or instruction.


Adverse Reactions

Metrosol's side effects are classified by frequency. Common reactions often include gastrointestinal disturbances such as nausea, diarrhea, vomiting, and a temporary metallic taste. Headache is also commonly reported.

Rare but serious adverse reactions documented in regulatory sources include central nervous system effects such as seizures and encephalopathy, as well as severe skin reactions (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis). Peripheral neuropathy (numbness or tingling) has been reported, particularly with prolonged use.

System Organ Class Common Examples
Gastrointestinal Disorders Nausea, metallic taste, diarrhea
Nervous System Disorders Headache, dizziness
Blood and Lymphatic System Reversible decrease in white blood cell count (leukopenia)

Safety Restrictions and Contraindications

Official labeling defines strict limitations for Metrosol use:

  • Alcohol Restriction: Consumption of alcoholic beverages or products containing propylene glycol must be strictly avoided during and for at least three days (72 hours) following treatment to prevent a severe disulfiram-like reaction.
  • Drug-Drug Interaction: Metrosol is contraindicated in patients who have taken the drug disulfiram within the last two weeks.
  • Specific Populations: Metrosol is contraindicated in patients with Cockayne syndrome due to the risk of acute liver failure. Use requires caution and potential dose adjustment in patients with severe hepatic impairment (severe liver disease).

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented signs and required emergency actions in the event of a Metrosol (Metronidazole) overdose, based on regulatory labeling.


Documented Overdose Manifestations

System Affected Symptoms and Signs
Gastrointestinal Nausea, Vomiting
Neurological (Severe) Convulsive seizures, Ataxia (loss of muscle coordination)
Peripheral Nervous Peripheral neuropathy (numbness, pain, burning, or tingling in the extremities)

Official Emergency Actions and Management

In cases of suspected overdose, immediate medical help must be sought. Emergency services (911) must be called immediately if the affected person collapses, has a seizure, experiences trouble breathing, or cannot be awakened. Consultation with the poison control helpline is also advised.

Management consists of symptomatic and supportive therapy, as no specific antidote for Metronidazole overdose is known. The drug and its metabolites are significantly removable by hemodialysis, which is a consideration in acute management. These severe neurological effects constitute the primary trigger for urgent medical intervention and hospital monitoring.

Therapeutic Uses of Metrosol

What Metrosol Treats: Main Uses and Benefits

Metrosol is commonly used to manage conditions characterized by symptoms related to inflammatory or irritative states caused by susceptible anaerobic bacteria and specific protozoal organisms. It is employed in a range of clinical contexts, including managing infections that may be serious or deep-seated, such as intra-abdominal abscesses, septicemia, and bone infections, as well as specific urogenital and gastrointestinal parasitic illnesses like Trichomoniasis, Amebiasis, and infectious colitis (C. difficile). It also assists in easing the challenging symptoms of Rosacea.

The medication is relevant when supportive symptom management is appropriate, and contributes to symptomatic relief that helps patients cope more steadily with difficult episodes. It assists with maintaining functional stability during periods of heightened discomfort.

“Metrosol is applied across domains where additional symptomatic support is needed, helping to address symptom clusters that may become intense or disruptive.”

Quick Fact: Support for Infection-Related Discomfort

The primary therapeutic benefit of Metrosol is centered on easing the overall symptom burden associated with these targeted infections, and it contributes to day-to-day comfort and stability during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Metrosol?

The eligibility for Metrosol (Metronidazole) is strictly defined by regulatory documents, distinguishing between populations that are permitted, restricted, or absolutely contraindicated. Use is generally permitted for adults and pediatric patients for specific, approved indications, such as Amebiasis.


Eligibility Scope

  • Populations for whom use is contraindicated: Individuals with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. The medicine is also contraindicated in patients who have taken disulfiram within 14 days or who consume alcohol or propylene glycol during therapy and for at least three days afterward. Patients with Cockayne Syndrome must not use this medicine due to the risk of acute hepatic failure.
  • Conditional/Restricted Use: Patients with severe hepatic impairment (Child-Pugh C) require a mandated dose reduction due to impaired clearance. Those with end-stage renal disease or severe central nervous system disease require close monitoring. Use during the first trimester of pregnancy is often restricted or contraindicated for certain treatments, and interruption of breastfeeding may be advised. Geriatric patients require monitoring due to altered drug clearance.

Resulting Eligibility Structure

Official eligibility statements define clear exclusions based on absolute prohibitions (Disulfiram, Alcohol, Hypersensitivity) and conditional eligibility based on metabolic capacity and organ function (Severe Liver Impairment), which require specific regulatory management.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metrosol (metronidazole) has documented interaction patterns that require specific regulatory conditions for co-administration, established through official prescribing information.

Formal Restrictions and Timing Rules

Substance/Medicine Interaction Classification Required Restriction/Condition
Disulfiram Contraindicated Must not be administered if Disulfiram was taken within the last two weeks.
Alcohol / Propylene Glycol Mandatory Avoidance Consumption must be avoided during and for at least three days after treatment ceases.

Exposure-Modifying Interactions

Co-administration with Metrosol can officially alter the plasma concentration or effect of other medicines:

  • Increased Effect/Exposure: Metrosol is reported to potentiate the anticoagulant effect of Warfarin and related Coumarin agents, resulting in the prolongation of prothrombin time. Metrosol also causes the elevation of plasma concentrations for Lithium, Busulfan, and Ciclosporin, and reduces the clearance of 5-fluorouracil, potentially leading to increased toxicity of those co-administered drugs.
  • Reduced Metrosol Exposure: Medicines such as Phenobarbital and Phenytoin are documented to accelerate the metabolism of Metrosol, resulting in a reduced concentration or shorter half-life of the antimicrobial agent.

Population-Specific Notes

In patients with Severe Hepatic Impairment, substantial impairment of Metrosol clearance can occur, leading to significant accumulation. Regulatory documents also note that Metrosol is efficiently removed during hemodialysis.

Mechanism of Action

Selective Bioactivation in Low-Oxygen Environments

The function of Metrosol, whose active compound is Metronidazole, relies on its role as an inactive prodrug. The mechanism demonstrates selectivity, requiring chemical activation by specific electron-transport proteins, such as ferredoxin, which are present in susceptible anaerobic bacteria and protozoa. This process consumes electrons generated by the microbe's low-oxygen metabolism, chemically reducing the drug's nitro group to create highly reactive, cytotoxic intermediates.


Destruction of Microbial DNA and Synthesis Inhibition

Once activated, the highly reactive intermediates, including nitro radical anions, immediately initiate a cytotoxic cascade by attacking the microbe's DNA. This action leads to the fragmentation of the DNA strands and the destabilization of the helix, resulting in the irreversible inhibition of nucleic acid synthesis and repair. This direct assault on the genetic material is the molecular event that produces the drug's bactericidal and protozoacidal physiological effect.


Mechanistic Limitation by Oxygen

A functional limitation of this mechanism is its oxygen sensitivity. In the presence of oxygen (found in aerobic organisms and host cells), the toxic intermediates are quickly re-oxidized back into the inactive parent drug, preventing the necessary accumulation of cytotoxic radicals. This chemical constraint explains why the mechanism of action is limited exclusively to organisms thriving in anaerobic (low-oxygen) environments.

Dosage and Administration Information

How Metrosol is Used — Official Administration Guidelines

Metrosol (Metronidazole) is administered via multiple routes, including oral (tablets, capsules, suspension), intravenous (IV) infusion, and localized topical/intravaginal forms. The choice of route depends on the clinical setting, with IV administration often initiating therapy for serious systemic courses, followed by a transition to the oral form.


Dosing and Administration Schedule

Standard adult systemic dosing involves a weight-based loading dose of 15 mg/kg IV, followed by a maintenance dose of 7.5 mg/kg administered every six hours (q6hr) or a fixed 500 mg dose every eight hours. Oral regimens for parasitic infections may include a single 2 g dose or 250 mg three times daily (TID) for seven days. The maximum recommended dose for systemic use is 4 g per day.

Treatment duration is typically 7 to 10 days for established bacterial courses, or 5 to 10 days for amebiasis.


Contextual Use and Adjustments

Oral preparations are generally taken with food to minimize gastric discomfort. However, the instructions for the extended-release oral tablet mandate administration on an empty stomach, taken one hour before or two hours after a meal, and the tablet must be swallowed whole.

For the IV form, the dose must be infused slowly over a period of 30 to 60 minutes. Dose reductions of 50% are required in patients with severe hepatic impairment, and supplemental dosing is to be considered after hemodialysis due to drug clearance.

If a scheduled dose is missed, it should be taken as soon as it is remembered, but if it is nearly time for the next dose, the missed dose is skipped to prevent a double dose.

Recent Clinical Evidence

Metrosol: Recent Clinical Evidence

This overview describes the types of clinical research conducted on Metrosol (Metronidazole) to characterize the available evidence, what studies have monitored so far, and what aspects remain uncertain according to scientific literature. This information is based on findings reported by regulatory bodies and peer-reviewed sources.


Evidence for Core Infectious Conditions

For complicated internal infections (e.g., abscesses), research relies primarily on Randomized Controlled Trials (RCTs) where Metrosol was examined as part of combination regimens. Studies tracked outcomes like Clinical Cure against pre-determined metrics. However, the full contribution of Metrosol alone remains uncertain, as most data stem from combination therapies, and evidence is limited for some high-risk adult groups.

For Infectious Colitis (C. difficile), the research explores Systematic Reviews and large Observational Cohort Studies that monitored outcomes like diarrhea resolution and Recurrence rates. Findings indicate that outcomes measured for resolution were frequently reported early in the study period. Limitations include mixed comparative evidence against other treatments and limited data derived from randomized studies in the pediatric population.

For Protozoal Infections (Trichomoniasis and Amebiasis), the research is often categorized as having a High evidence level, reflecting the quantity of established trials. These studies examined Microbiological Eradication in both adults and children. A key research limitation is the ongoing documentation of localized drug resistance in certain strains, which research continues to monitor.


Evidence for Topical and Special Populations

Research examined the localized use of topical Metrosol in the context of Rosacea, tracking changes related to surface lesions and erythema (redness). These studies focus exclusively on patient-reported outcomes describing perceived discomfort and do not explore systemic anti-infective outcomes.

Regarding Special Populations, research has included studies on infants with intra-abdominal infections and pharmacokinetic analyses for adults with hepatic or renal impairment. However, long-term outcomes are not fully established for many indications, as initial follow-up durations were limited. Overall, comparative evidence is often lacking in many contexts, and subgroup findings are uncertain for specific high-risk adult cohorts.

Frequently Asked Questions (FAQ)

Common questions about Metrosol (FAQ)


Q: Is Metrosol considered a long-term treatment or short-term?

Metrosol is generally prescribed for a short and defined period, typically ranging between 5 and 10 days for specific infections. Official information states that prolonged use or high doses have been associated with potential risks, including effects on the nervous system and a decrease in white blood cell count.


Q: Will I definitely get the side effects listed for Metrosol?

No, it is not certain that every listed side effect will occur. Official product information classifies adverse reactions by their documented frequency, such as common or rare, indicating that these reactions are possible but not guaranteed. For instance, metallic taste and headache are noted as common reactions.


Q: What kind of studies were done to get Metrosol approved?

Regulatory approval for Metrosol is based on clinical data derived from trials that examine its effectiveness and safety profile. These studies often include Randomized Controlled Trials (RCTs) which track outcomes such as clinical cure against pre-determined metrics. This evidence is used to characterize the drug's established therapeutic purpose.


Q: Is there a generic version of Metrosol available?

Yes, the active ingredient in Metrosol, known as metronidazole, is available as a generic drug. Regulatory classification indicates the generic is considered to have the same clinical effect and safety profile as the corresponding brand-name product.


Q: Can Metrosol be taken with supplements or vitamins?

The official product labeling does not list general vitamins or supplements as a formal contraindication or interaction. However, the mandatory requirement to avoid alcohol, established in the official labeling, still applies and should be considered if taking any liquid supplements or herbal tinctures.


Q: Can Metrosol cause weight gain or weight loss?

Official documents concerning the drug's safety profile indicate that weight loss, described as anorexia, is documented as a possible side effect of Metrosol. Weight gain is not frequently noted among the documented adverse reactions.


Q: Can Metrosol affect sleep or cause drowsiness?

Yes, official product labeling indicates that Metrosol can affect sleep. Specifically, trouble sleeping, or insomnia, is documented as a possible side effect. Other nervous system effects, such as dizziness, are also noted in the product labeling.


Q: Is Metrosol safe for people with kidney problems?

Official information notes that for patients with severe renal impairment or end-stage renal disease (ESRD), there is a potential for drug metabolites to accumulate. Regulatory guidance indicates monitoring is typically warranted in these circumstances for associated adverse events, especially if the patient is not undergoing hemodialysis.


Q: Is Metrosol safe for people with liver problems?

The eligibility for Metrosol is restricted for those with severe liver problems. Patients with severe hepatic impairment require a mandated dose reduction due to impaired clearance of the drug. Furthermore, the medicine is strictly contraindicated for individuals diagnosed with Cockayne syndrome due to the risk of acute liver failure.


Q: Can elderly patients use Metrosol?

Yes, Metrosol is used in geriatric patients for approved indications. Due to the potential for altered drug clearance in this age group, regulatory documents indicate that monitoring for associated adverse events is typically warranted.


Q: Are there any known interactions between Metrosol and caffeine?

There is no formal restriction or contraindication for caffeine documented as a drug-drug interaction in the official product labeling. The mandatory avoidance rule applies specifically to alcohol and the drug Disulfiram.


Q: Are there certain foods or drinks I should avoid while on Metrosol?

Consumption of alcohol or products containing propylene glycol must be avoided during and for at least three days after treatment. The extended-release oral tablet is described as being taken on an empty stomach, while other forms are generally taken with food to minimize gastric discomfort.


Q: Can Metrosol cause changes in mood or anxiety?

Yes, effects on the central nervous system (CNS) are documented as adverse reactions. Official sources note reports of changes in mood, including confusion, depression, irritability, and in rare cases, hallucinations or delusions.


Q: Do children or teenagers take Metrosol?

Yes, Metrosol is approved for use in pediatric patients for specific approved conditions, such as amebiasis and certain anaerobic infections. The appropriate dose is determined by a physician and is calculated based on the child's body weight.


Q: Why is Metrosol sometimes mentioned in discussions about drug resistance?

Official product labeling includes a usage warning intended to address drug resistance. This warning states that Metrosol should only be used to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria. This measure is intended to help limit the development of drug-resistant bacteria.


Q: What is the expected long-term safety profile of Metrosol?

Metrosol is generally utilized for short courses of treatment. The official documents state that long-term outcomes are not fully established for many indications, and prolonged or high-dose use is associated with potential risks such as peripheral neuropathy (numbness or tingling) and toxicity to the central nervous system.


Q: Does Metrosol require any special monitoring or blood tests?

While Metrosol can cause a reversible decrease in white blood cell count (leukopenia), routine blood tests are not universally mandated for all patients. However, monitoring for adverse events is specifically recommended in official documents for certain populations, including elderly patients and those with severe hepatic or renal impairment.


Q: Are there differences between the brand-name Metrosol and its generic equivalent?

Regulatory bodies approve generic versions as therapeutically equivalent to the brand-name product, which in this case is Metrosol. This regulatory classification means that the generic product is expected to have the same clinical effect and safety profile when administered under the same conditions in the labeling.


Q: What common over-the-counter cold medicines interact with Metrosol?

Formal contraindications are established only for prescription drugs like Warfarin and the substances alcohol and disulfiram. The official product labeling does not list any particular over-the-counter cold medicines as having formal, mandated restrictions for co-administration.


Q: Does Metrosol have any warnings related to sun exposure?

Yes, official safety information advises patients to limit unnecessary or prolonged exposure to sunlight while using Metrosol. This precaution is noted because the medicine may increase skin sensitivity to the sun.


Q: What is the purpose of the black box warning on Metrosol's label, if any?

A Boxed Warning, the most serious type of warning issued by the FDA, is present on the labeling for the oral form of metronidazole. This warning references cancer findings observed in animal studies and states that unnecessary use of the drug should be avoided.


Q: Can Metrosol affect fertility in men or women?

Official information does not indicate a clear evidence base suggesting that Metrosol reduces fertility in men or women.


Q: What are the main things I need to tell my doctor before starting Metrosol?

Key facts used to determine eligibility and restrictions are described in official documents. These include a history of hypersensitivity to the drug, recent use of disulfiram (within 14 days), pregnancy status, and the presence of severe hepatic (liver) or renal (kidney) impairment.


Q: Is Metrosol known to interact with herbal remedies like St. John's Wort?

Official safety documents and product labeling do not list St. John’s Wort or similar common herbal remedies as a formal, mandated interaction or contraindication for Metrosol. The requirement to avoid alcohol, established in the official labeling, still applies to any liquid herbal remedies or tinctures that may contain it.

How should Metrosol be stored and disposed of?

How to Store and Dispose of Metrosol

Storage of Metrosol (Metronidazole) must comply with specific temperature and environmental constraints to maintain stability.


Required Storage Conditions

Dosage Form Temperature Range Special Requirements
Oral (Tablets/Capsules) 20^circ to 25 C (USP Controlled Room Temperature) Store in a well-closed, child-resistant container.
Intravenous (IV) Solution) 20^circ to 25 C (USP Controlled Room Temperature) Protect from light and do not refrigerate (to prevent precipitation).

Handling and Disposal

Metrosol must be kept out of the reach of children. The IV solution should remain in its aluminum overwrap until use. Any unused portion of the single-dose intravenous container must be discarded. All expired or unused product must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metrosol found in:

A-Z Index: